Resultats globals: 11 registres trobats en 0.02 segons.
Articles, 10 registres trobats
Documents de recerca, 1 registres trobats
Articles 10 registres trobats  
1.
469.5 KB Targeted deep sequencing of CD34+ cells from peripheral blood can reproduce bone marrow molecular profile in myelodysplastic syndromes / Martin, Roman (University Medical Center Göttingen) ; Acha, Pamela (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Ganster, Christina (University Medical Center Göttingen) ; Palomo Sanchís, Laura (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Dierks, Sascha (University Medical Center Göttingen) ; Fuster-Tormo, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Mallo, Maria del Mar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Ademà, Vera (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Gómez-Marzo, Paula (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; De Haro, Nuri (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Solanes, Neus (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Zamora, Lurdes (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Shirneshan, Katayoon (University Medical Center Göttingen) ; Flach, Johanna (University Medical Center Göttingen) ; Braulke, Friederike (University Medical Center Göttingen) ; Schanz, Julie (University Medical Center Göttingen) ; Kominowski, Arkadiusz (University Medical Center Göttingen) ; Stromburg, Martin (University Medical Center Göttingen) ; Brockmann, Alina (University Medical Center Göttingen) ; Trümper, Lorenz (University Medical Center Göttingen) ; Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Haase, Detlef (University Medical Center Göttingen) ; Universitat Autònoma de Barcelona
2018 - 10.1002/ajh.25089
American Journal of Hematology, Vol. 93 (april 2018) , p. E152-E154  
2.
17 p, 2.3 MB Analysis of Intratumoral Heterogeneity in Myelodysplastic Syndromes with Isolated del(5q) Using a Single Cell Approach / Acha, Pamela (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Mallo, Mar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Manzanares Mileo, Ana (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Grau, Javier (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Marcé, Silvia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Granada, Isabel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Rodríguez-Luaces, Marta (Hospital Verge de la Cinta de Tortosa) ; Diez-Campelo, María (Hospital Universitario de Salamanca) ; Zamora, Lurdes (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Sole, F. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Palomo Sanchís, Laura (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Fuster-Tormo, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Universitat Autònoma de Barcelona
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematological diseases. Among them, the most well characterized subtype is MDS with isolated chromosome 5q deletion (MDS del(5q)), which is the only one defined by a cytogenetic abnormality that makes these patients candidates to be treated with lenalidomide. [...]
2021 - 10.3390/cancers13040841
Cancers, Vol. 13 Núm. 4 (2021) , p. 841  
3.
11 p, 1.4 MB Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19 / Barbui, Tiziano (Papa Giovanni XXIII Hospital. FROM Research Foundation) ; De Stefano, Valerio (Fondazione Policlinico "A. Gemelli" IRCCS. Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University) ; Alvarez-Larran, Alberto (Hospital Clínic i Provincial de Barcelona) ; Iurlo, Alessandra (Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico. Hematology Division) ; Masciulli, Arianna (Papa Giovanni XXIII Hospital. FROM Research Foundation) ; Carobbio, Alessandra (Papa Giovanni XXIII Hospital. FROM Research Foundation) ; Ghirardi, Arianna (Papa Giovanni XXIII Hospital. FROM Research Foundation) ; Ferrari, Alberto (Papa Giovanni XXIII Hospital. FROM Research Foundation) ; Cancelli, Valeria (Spedali Civili) ; Elli, Elena Maria (ASST Monza. Hematology Division and Bone Marrow Transplant, San Gerardo Hospital) ; Andrade-Campos, Marcio Miguel (Institut Hospital del Mar d'Investigacions Mèdiques) ; Kabat, Mercedes Gasior (Hospital Universitario La Paz (Madrid)) ; Kiladjian, Jean-Jaques (Hospital Saint-Louis) ; Palandri, Francesca (Azienda Ospedaliero-Universitaria di Bologna) ; Benevolo, Giulia (AOU Città della Salute e della Scienza di Torino) ; Garcia-Gutierrez, Valentin (Hospital Universitario Ramón y Cajal (Madrid)) ; Fox, Maria Laura (Vall d'Hebron Institut d'Oncologia) ; Foncillas, Maria Angeles (Hospital Universitario Infanta Leonor) ; Morcillo, Carmen Montoya (Complejo Hospitalario Universitario de Albacete) ; Rumi, Elisa (University of Pavia. Department of molecular medicine) ; Osorio, Santiago (Hospital Gregorio Marañón (Madrid)) ; Papadopoulos, Petros (Hospital Clínico San Carlos (Madrid)) ; Bonifacio, Massimiliano (Ospedale Policlinico "G.B. Rossi", Borgo Roma) ; Cervantes, Keina Susana Quiroz (Hospital Universitario de Mostoles) ; Serrano, Miguel Sagues (ICO L'Hospitalet-Hospital Moises Broggi, Sant Joan Despì) ; Carreno-Tarragona, Gonzalo (Hospital Universitario 12 de Octubre (Madrid)) ; Sobas, Marta Anna (Wroclaw Medical University. Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation) ; Lunghi, Francesca (IRCCS Ospedale San Raffaele) ; Patriarca, Andrea (AOU Maggiore della Carità, Novara, Italy) ; Elorza, Begoña Navas (Hospital Moncloa, Madrid, Spain) ; Angona, Anna (Hospital Universitari de Girona Doctor Josep Trueta) ; Mazo, Elena Magro (Hospital Universitario Principe de Asturias) ; Koschmieder, Steffen (RWTH Aachen University. Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine) ; Carli, Giuseppe (Ospedale San Bortolo) ; Cuevas, Beatriz (Hospital Universitario de Burgos) ; Hernandez-Boluda, Juan Carlos (Hospital Clínic Universitari (València)) ; Abadia, Emma Lopez (Hospital General de Elche) ; Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Guglielmelli, Paola (University of Florence. Center Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, Azienda Ospedaliera Universitaria Careggi) ; Garrote, Marta (Hospital Clínic i Provincial de Barcelona) ; Cattaneo, Daniele (Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico. Hematology Division) ; Daffini, Rosa (Spedali Civili) ; Cavalca, Fabrizio (ASST Monza. Hematology Division and Bone Marrow Transplant, San Gerardo Hospital) ; Bellosillo Paricio, Beatriz (Institut Hospital del Mar d'Investigacions Mèdiques) ; Benajiba, Lina (Hospital Saint-Louis) ; Curto-Garcia, Natalia (Guy's and St. Thomas' NHS Foundation Trust) ; Bellini, Marta (ASST Papa Giovanni XXIII, Bergamo, Italy) ; Betti, Silvia (Fondazione Policlinico "A. Gemelli" IRCCS. Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University) ; Harrison, Claire (Guy's and St. Thomas' NHS Foundation Trust) ; Rambaldi, Alessandro (Università degli Studi di Milano) ; Vannucchi, Alessandro Maria (University of Florence. Center Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, Azienda Ospedaliera Universitaria Careggi) ; Universitat Autònoma de Barcelona
In a multicenter European retrospective study including 162 patients with COVID-19 occurring in essential thrombocythemia (ET, n = 48), polycythemia vera (PV, n = 42), myelofibrosis (MF, n = 56), and prefibrotic myelofibrosis (pre-PMF, n = 16), 15 major thromboses (3 arterial and 12 venous) were registered in 14 patients, of whom all, but one, were receiving LMW-heparin prophylaxis. [...]
2021 - 10.1038/s41408-021-00417-3
Blood Cancer Journal, Vol. 11 (february 2021)  
4.
15 p, 3.4 MB Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS / Kuendgen, A. (Department of Hematology. Oncology. and Clinical Immunology. University Hospital Duesseldorf) ; Nomdedeu, Meritxell (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Tuechler, H. (Boltzmann Institute for Leukemia Research. Hanusch Hospital) ; Garcia-Manero, G. (Department of Leukemia. MD Anderson Cancer Center) ; Komrokji, R.S. (Department of Malignant Hematology. H Lee Moffitt Cancer Center) ; Sekeres, M.A. (Leukemia Program. Department of Hematology and Medical Oncology. Taussig Cancer Institute. Cleveland Clinic) ; Della Porta, M.G. (Cancer Center - IRCCS Humanitas Research Hospital & Humanitas University) ; Cazzola, M. (Department of Hematology Oncology. IRCCS Policlinico San Matteo Foundation) ; DeZern, A.E. (Sidney Kimmel Comprehensive Cancer Center. Johns Hopkins University) ; Roboz, G.J. (Weill Cornell Medicine and The New York Presbyterian Hospital) ; Steensma, D.P. (Dana-Farber Cancer Institute) ; Van de Loosdrecht, A.A. (Vrije Universiteit Amsterdam) ; Schlenk, R.F. (Department of Internal Medicine V. Heidelberg University Hospital) ; Grau, J. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Calvo, Xavier (Institut Hospital del Mar d'Investigacions Mèdiques) ; Blum, S. (Service of Hematology. University Hospital Lausanne) ; Pereira, A. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Valent, P. (Department of Internal Medicine I. Division of Hematology & Hemostaseology and Ludwig Boltzmann Institute for Hematology and Oncology. Medical University of Vienna) ; Costa, D. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Giagounidis, A. (Department of Oncology. Hematology and Palliative Care. Marienhospital Duesseldorf) ; Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Döhner, H. (Department of Internal Medicine III. University Hospital Ulm) ; Platzbecker, U. (University Hospital Leipzig) ; Pedro, Carme (Hospital del Mar (Barcelona, Catalunya)) ; Lübbert, M. (Department of Hematology. Oncology and Stem Cell Transplantation. University Medical Center Freiburg. Faculty of Medicine) ; Oiartzabal, I. (Clinical Hematology Department. Hospital Universitario Araba) ; Díez-Campelo, M. (Clinical Hematology Department. Hospital Universitario de Salamanca (HUSA)) ; Cedena, M.T. (Hospital Universitario 12 de Octubre (Madrid)) ; Machherndl-Spandl, S. (1st. Internal Department - Hematology with stem cell transplants. Hemostaseology and Medical Oncology. Elisabethinen Hospital) ; López-Pavía, M. (Clinical Hematology Department. Hospital General Universitari de València) ; Baldus, C.D. (Department of Hematology and Oncology. University Hospital Schleswig-Holstein. Campus Kiel) ; Martinez-de-Sola, M. (Parc Taulí Hospital Universitari) ; Stauder, R. (Department of Internal Medicine V (Hematology and Oncology). Innsbruck Medical University) ; Merchan, B. (Hospital Universitari Vall d'Hebron) ; List, A. (Department of Malignant Hematology. H Lee Moffitt Cancer Center) ; Ganster, C. (Department of Hematology and Medical Oncology. University Medical Center Göttingen) ; Schroeder, T. (Department of Hematology. Oncology. and Clinical Immunology. University Hospital Duesseldorf) ; Voso, M.T. (Department of Biomedicine and Prevention. Tor Vergata University) ; Pfeilstöcker, M. (Hanusch Krankenhaus Wien) ; Sill, H. (Medizinische Universität Graz) ; Hildebrandt, B. (Institute of Human Genetics. University Duesseldorf) ; Esteve Reyner, Jordi (Hospital Clínic i Provincial de Barcelona) ; Nomdedeu, B. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Cobo, F. (Clinical Hematology Department. Hospital Quirón Teknon) ; Haas, R. (Department of Hematology. Oncology. and Clinical Immunology. University Hospital Duesseldorf) ; Sole, F. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Germing, U. (Department of Hematology. Oncology. and Clinical Immunology. University Hospital Duesseldorf) ; Greenberg, P.L. (Stanford University Cancer Center) ; Haase, D. (Department of Hematology and Medical Oncology. University Medical Center Göttingen) ; Sanz, G. (Hospital Universitari i Politècnic La Fe de Valencia) ; Universitat Autònoma de Barcelona
In the current World Health Organization (WHO)-classification, therapy-related myelodysplastic syndromes (t-MDS) are categorized together with therapy-related acute myeloid leukemia (AML) and t-myelodysplastic/myeloproliferative neoplasms into one subgroup independent of morphologic or prognostic features. [...]
2020 - 10.1038/s41375-020-0917-7
Leukemia, 2020  
5.
11 p, 1.5 MB Comparison of flow-FISH and MM-qPCR telomere length assessment techniques for the screening of telomeropathies / Ferreira, M.S.V. (Department of Hematology. Oncology. Hemostaseology and Stem Cell Transplantation. Medical Faculty. RWTH Aachen University. University Hospital Aachen) ; Kirschner, M. (Department of Hematology. Oncology. Hemostaseology and Stem Cell Transplantation. Medical Faculty. RWTH Aachen University. University Hospital Aachen) ; Halfmeyer, I. (Department of Hematology. Oncology. Hemostaseology and Stem Cell Transplantation. Medical Faculty. RWTH Aachen University. University Hospital Aachen) ; Estrada, Natalia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Isfort, S. (Department of Hematology. Oncology. Hemostaseology and Stem Cell Transplantation. Medical Faculty. RWTH Aachen University. University Hospital Aachen) ; Vieri, M. (Department of Hematology. Oncology. Hemostaseology and Stem Cell Transplantation. Medical Faculty. RWTH Aachen University. University Hospital Aachen) ; Zamora, Lurdes (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Abels, A. (Department of Hematology. Oncology. Hemostaseology and Stem Cell Transplantation. Medical Faculty. RWTH Aachen University. University Hospital Aachen) ; Bouillon, A.S. (Department of Hematology. Oncology. Hemostaseology and Stem Cell Transplantation. Medical Faculty. RWTH Aachen University. University Hospital Aachen) ; Begemann, M. (Institute of Human Genetics. Medical Faculty. RWTH Aachen University) ; Schemionek, M. (Department of Hematology. Oncology. Hemostaseology and Stem Cell Transplantation. Medical Faculty. RWTH Aachen University. University Hospital Aachen) ; Maurer, A. (Department of Hematology. Oncology. Hemostaseology and Stem Cell Transplantation. Medical Faculty. RWTH Aachen University. University Hospital Aachen) ; Koschmieder, S. (Department of Hematology. Oncology. Hemostaseology and Stem Cell Transplantation. Medical Faculty. RWTH Aachen University. University Hospital Aachen) ; Wilop, S. (Department of Hematology. Oncology. Hemostaseology and Stem Cell Transplantation. Medical Faculty. RWTH Aachen University. University Hospital Aachen) ; Panse, J. (Department of Hematology. Oncology. Hemostaseology and Stem Cell Transplantation. Medical Faculty. RWTH Aachen University. University Hospital Aachen) ; Brümmendorf, T.H. (Department of Hematology. Oncology. Hemostaseology and Stem Cell Transplantation. Medical Faculty. RWTH Aachen University. University Hospital Aachen) ; Beier, F. (Department of Hematology. Oncology. Hemostaseology and Stem Cell Transplantation. Medical Faculty. RWTH Aachen University. University Hospital Aachen) ; Universitat Autònoma de Barcelona
Assessment of telomere length (TL) in peripheral blood leukocytes is part of the diagnostic algorithm applied to patients with acquired bone marrow failure syndromes (BMFSs) and dyskeratosis congenita (DKC). [...]
2020 - 10.1111/nyas.14248
Annals of the New York Academy of Sciences, Vol. 1466 Núm. 1 (2020) , p. 93-103  
6.
14 p, 3.0 MB Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival / Cabezón, Marta (Universitat Autònoma de Barcelona. Departament de Medicina) ; Malinverni, Roberto (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Bargay, Joan (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ; Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Marcé, Silvia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Garrido, A. (Institut d'Investigació Biomèdica Sant Pau) ; Tormo, M. (Hospital Clínic Universitari (València)) ; Arenillas, Leonor (Hospital del Mar (Barcelona, Catalunya)) ; Coll, R. (Hospital Universitari de Girona Doctor Josep Trueta) ; Borras, J. (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ; Jiménez, María José (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Hoyos Colell, Montserrat (Institut d'Investigació Biomèdica Sant Pau) ; Valcárcel, David (Hospital Universitari Vall d'Hebron) ; Escoda, L. (Hospital Universitari Joan XXIII de Tarragona) ; Vall-Llovera, F. (Hospital Universitari MútuaTerrassa) ; Garcia, A. (Hospital Arnau de Vilanova. Hematology Service) ; Font, L. L. (Hematology Service, Hospital Verge de La Cinta, Tortosa, Spain) ; Rámila, E. (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Buschbeck, Marcus (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Zamora, Lurdes (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Epigenetic therapy, using hypomethylating agents (HMA), is known to be effective in the treatment of high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) patients who are not suitable for intensive chemotherapy and/or allogeneic stem cell transplantation. [...]
2021 - 10.1186/s13148-021-01002-y
Clinical Epigenetics, Vol. 13 (january 2021)  
7.
11 p, 2.0 MB Immediate effects of dasatinib on the migration and redistribution of naïve and memory lymphocytes associated with lymphocytosis in chronic myeloid leukemia patients / Colom-Fernández, B. (Instituto de Investigación Hospital Universitario de la Princesa) ; Kreutzman, A. (Instituto de Investigación Hospital Universitario de la Princesa) ; Marcos-Jiménez, A. (Instituto de Investigación Hospital Universitario de la Princesa) ; García-Gutiérrez, V. (Hospital Universitario Ramón y Cajal (Madrid)) ; Cuesta-Mateos, C. (Instituto de Investigación Hospital Universitario de la Princesa) ; Portero-Sainz, I. (Instituto de Investigación Hospital Universitario de la Princesa) ; Pérez-García, Y. (Instituto de Investigación Hospital Universitario de la Princesa) ; Casado, L.F. (Servicio de Hematología y Hemoterapia. Hospital Virgen de la Salud) ; Sánchez-Guijo, F. (Servicio de Hematología y Hemoterapia. IBSAL-Hospital Universitario de Salamanca) ; Martínez-López, J. (Hospital 12 de Octubre (Madrid)) ; Ayala, R.M. (Hospital 12 de Octubre (Madrid)) ; Boqué, C. (Institut Català d'Oncologia) ; Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Montero, I. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Soto, C. (Servicio de Hematología. Hospital Povisa) ; Paz, R. (Hospital Universitario La Paz (Madrid)) ; Silva, G. (Instituto de Investigación Hospital Universitario de la Princesa) ; Vega-Piris, L. (Instituto de Investigación Sanitaria La Princesa) ; Steegmann, J.L. (Instituto de Investigación Hospital Universitario de la Princesa) ; Muñoz Calleja, Cecilia (Instituto de Investigación Hospital Universitario de la Princesa) ; Universitat Autònoma de Barcelona
Introduction: Dasatinib is a dual SRC/ABL tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML) that is known to have unique immunomodulatory effects. In particular, dasatinib intake typically causes lymphocytosis, which has been linked to better clinical response. [...]
2019 - 10.3389/fphar.2019.01340
Frontiers in Pharmacology, Vol. 10 (2019) , p. 1340  
8.
10 p, 1.6 MB International sentinel site surveillance of patients with transfusional hemosiderosis treated with deferasirox in actual practice setting / El-Beshlawy, Amal (Cairo University) ; Inusa, Baba (Evelina Children's Hospital) ; Beneitez Pastor, David (Hospital Universitari Vall d'Hebron) ; Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Duran Nieto, Maria Soledad (Hospital Materno Infantil de Jaén) ; Bruederle, Andreas (Novartis Pharma AG) ; Azmon, Amin (Novartis Pharma AG, Switzerland) ; Gilotti, Geralyn (Novartis Pharmaceuticals Corporation, USA) ; Elalfy, Mohsen (Ain Shams University (El Caire, Egipte)) ; Universitat Autònoma de Barcelona
Objective:The study evaluates the long-term deferasirox treatment of adult and pediatricpatients with chronic transfusional iron overload in clinical practice. Methods:In this non-interventional study, patients were observed for up to 3 years frominitiation of deferasirox treatment both prospectively and retrospectively for up to 1 yearprior to enrollment. [...]
2019 - 10.1080/16078454.2018.1558758
Hematology, 2019  
9.
14 p, 1.9 MB Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine / Cabezón, Marta (Universitat Autònoma de Barcelona. Departament de Medicina) ; Bargay, Joan (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ; Xicoy, Blanca (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; García, Olga (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Borrás, Josep (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ; Tormo, Mar (Hospital Clínic Universitari (València)) ; Marcé, Sílvia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Pedro, Carme (Hospital del Mar (Barcelona, Catalunya)) ; Valcárcel, David (Hospital Universitari Vall d'Hebron) ; Jiménez, Maria José (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Guàrdia, Ramón (Hospital Universitari de Girona Doctor Josep Trueta) ; Palomo Sanchís, Laura (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Brunet, Salut (Institut d'Investigació Biomèdica Sant Pau) ; Vall-Llovera, Ferran (Hospital Universitari MútuaTerrassa) ; Garcia, Antoni (Hospital Arnau de Vilanova (Lleida)) ; Feliu, Evarist (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Zamora, Lurdes (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Universitat Autònoma de Barcelona
Myelodysplastic syndromes (MDS) are stem cell disorders caused by various gene abnormalities. We performed targeted deep sequencing in 39 patients with high-risk MDS and secondary acute myeloid leukemia (sAML) at diagnosis and follow-up (response and/or relapse), with the aim to define their mutational status, to establish if specific mutations are biomarkers of response to 5-azacytidine (AZA) and/or may have impact on survival. [...]
2018 - 10.18632/oncotarget.25046
Oncotarget, Vol. 9 (april 2018) , p. 19342-19355  
10.
15 p, 2.2 MB Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features / Palomo Sanchis, Laura (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Garcia, Olga (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Arnan, Montse (ICO-Hospital Duran i Reynals. Hematology Service) ; Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Fuster García, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Cabezón, Marta (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Coll, Rosa (Hospital Universitari de Girona Doctor Josep Trueta) ; Ademà Llobet, Vera (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Grau Cat, Javier (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Jiménez, Maria-José (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Pomares, Helena (ICO-Hospital Duran i Reynals. Hematology Service) ; Marcé, Sílvia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Mallo, Mar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Millá, Fuensanta (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Alonso, Esther (ICO-Hospital Duran i Reynals. Hematology Service) ; Sureda, Anna (ICO-Hospital Duran i Reynals. Hematology Service) ; Gallardo Giralt, David (Hospital Universitari de Girona Doctor Josep Trueta) ; Feliu, Evarist (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Solé, Francesc (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Zamora, Lurdes (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Clonal cytogenetic abnormalities are found in 20-30% of patients with chronic myelomonocytic leukemia (CMML), while gene mutations are present in >90% of cases. Patients with low risk cytogenetic features account for 80% of CMML cases and often fall into the low risk categories of CMML prognostic scoring systems, but the outcome differs considerably among them. [...]
2016 - 10.18632/oncotarget.10937
Oncotarget, Vol. 7, Num. 35 (August 2016) , p. 57021-57035  

Documents de recerca 1 registres trobats  
1.
171 p, 1.4 MB Respuesta al tratamiento y pronóstico del linfoma de Hodgkin clásico en estadio avanzado y del linfoma/leucemia de Burkitt asociados a la infección por el virus de la inmunodeficiencia humana / Xicoy Cirici, Blanca ; Ribera Santasusana, J. M., (José María), dir. (Universitat Autònoma de Barcelona. Departament de Medicina) ; Feliu Frasnedo, Evaristo, dir. (Universitat Autònoma de Barcelona. Departament de Medicina) ; Universitat Autònoma de Barcelona. Departament de Medicina
El linfoma de Hodgkin (LH) y el linfoma-leucemia de Burkitt (LB) asociados a la infección por el virus de la inmunodeficiencia humana (VIH) se presentan en pacientes con un estado inmunológico menos deteriorado que el presente en otros tipos de linfoma. [...]
Human immunodeficiency virus (HIV) associated Hodgkin's lymphoma (HL) and Burkitt's lymphoma/leukemia (BL) arise in patients with less impaired immune function than in other types of lymphomas. These patients have been traditionally treated with non-intensive chemotherapy (QT) schedules, mainly due to their impaired immune function, the risk of opportunistic infections (OI) and early deaths under treatment, thereby explaining their poor outcome. [...]

Bellaterra : Universitat Autònoma de Barcelona, 2012  

Vegeu també: autors amb noms similars
1 Xicoy, Bianca
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.